EUVIMEDOntdek EUVIMED
Open access · CC BY-NC-ND 4.0

Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis

Michael R Beck, Douglas B Hornick, Tahuanty A Pena iD, Sachinkumar B Singh, Brittany A Wright iD

Pediatric Pulmonology · 2023-05 · 58 (5) · 1569-1573

DOI: 10.1002/ppul.26362 ↗

At a glance

Journal article in Pediatric Pulmonology, 2023-03. Written by Michael R Beck and 4 co-authors. Institution: University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA. Major MEDLINE topics: Cystic Fibrosis. Cited 39 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIDDK NIH HHS.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Background

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have shown beneficial effects on both forced expiratory volume in 1 s (FEV 1 ) and frequency of pulmonary exacerbations in people with cystic fibrosis (CF). These positive outcomes may be related to changes in bacterial colonization within the lungs. Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is the first triple therapy CFTR modulator approved for use in people with CF 6 years and older. This study aimed to determine the impact of ELX/TEZ/IVA on the isolation of Pseudomonas aeruginosa (Pa), methicillin‐resistant and methicillin‐susceptible Staphylococcus aureus (MRSA and MSSA, respectively) in respiratory cultures.

Methods

A retrospective chart review of the electronic medical record at the University of Iowa was completed for individuals 12 years and older taking ELX/TEZ/IVA for at least 12 months. The primary outcome was determined by assessing bacterial cultures pre‐ and postinitiation of ELX/TEZ/IVA. Baseline demographic and clinical characteristics were summarized using mean and standard deviation for continuous outcomes and count and percentage for categorical outcomes. Culture positivity for Pa, MSSA, and MRSA was compared among enrolled subjects between pre‐ and posttriple combination therapy periods using an exact McNemar's test.

Results

One hundred and twenty‐four subjects prescribed ELX/TEZ/IVA for at least 12 months met the requirements for inclusion within our analysis. Culture positivity for Pa, MSSA, and MRSA was approximately 54%, 33%, and 31%, respectively, for the pre‐ELX/TEZ/IVA period. Prevalence decreased to approximately 30%, 32%, and 24% (−24.2% [ p < 0.0001], −0.7% [ p = 1.00], and −6.5% [ p = 0.0963], respectively) post‐ELX/TEZ/IVA. The source of bacterial culture was predominantly sputum (70.2%) in the pre‐ELX/TEZ/IVA group, whereas a throat source (66.1%) was more common post‐ELX/TEZ/IVA.

Conclusions

ELX/TEZ/IVA treatment has an appreciable impact on the detection of common bacterial pathogens in CF respiratory cultures. While previous studies have found a similar effect with single and double CFTR modulator therapies, this is the first single‐center study to show the impact of triple therapy, ELX/TEZ/IVA, on bacterial isolation from airway secretions.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisHumansCystic Fibrosis Transmembrane Conductance RegulatorRetrospective StudiesAminophenolsBenzodioxolesPseudomonas aeruginosaMutationPyrazolesPyridinesPyrrolidinesQuinolonesIndoles

Author keywords

CFTR modulatorsbacterial culturescystic fibrosis

Substances

Cystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxoleselexacaftorPyrazolesPyridinesPyrrolidinesivacaftorQuinolonestezacaftor

Authors and institutions

  • University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

ORCID profiles: Tahuanty A Pena, Brittany A Wright

Funding

  • NIDDK NIH HHS

Cite

APA

Beck, M. R., Hornick, D. B., Pena, T. A., Singh, S. B., & Wright, B. A. (2023). Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis. Pediatric Pulmonology, 58(5), 1569-1573. https://doi.org/10.1002/ppul.26362

Vancouver

Beck MR, Hornick DB, Pena TA, Singh SB, Wright BA. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis. Pediatric Pulmonology. 2023;58(5):1569-1573. doi:10.1002/ppul.26362

BibTeX
@article{Beck2023,
  author = {Beck, Michael R and Hornick, Douglas B and Pena, Tahuanty A and Singh, Sachinkumar B and Wright, Brittany A},
  title = {Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2023},
  volume = {58},
  number = {5},
  pages = {1569--1573},
  doi = {10.1002/ppul.26362}
}
Start for free →